Stock WINDTREE THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Windtree Therapeutics Inc OTC Bulletin Board

Equities

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Windtree Therapeutics Inc
Apr. 16 Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 11 North American Morning Briefing : Stock Futures -2- DJ

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Windtree Therapeutics : April'24 Corporate Presentation
PU
Windtree Therapeutics Announces Reverse Stock Split
AQ
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
AQ
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
Transcript : Windtree Therapeutics, Inc. - Shareholder/Analyst Call
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals
MT
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
AQ
Windtree Therapeutics, Inc. announced that it has received $1.5 million in funding
CI
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.
CI
Windtree Therapeutics, Inc. announced that it expects to receive $1.5 million in funding
CI
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Interim Chief Financial Officer and Principal Financial Officer
CI
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Principal Financial Officer
CI
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
AQ
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
CI
Windtree Therapeutics Engages Ladenburg to Evaluate Strategic Alternatives
CI
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
AQ
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
AQ
WINDTREE THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH LEE'S PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE ISTAROXIME, DUAL MECHANISM SERCA2A ACTIVATORS AND ROSTAFUROXIN FOR GREATER CHINA, ASIA PACIFIC REGION
AQ
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. WINT Stock
  4. Stock
  5. News Windtree Therapeutics Inc